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Background: Advanced glycation end products (AGEs) and receptor RAGE interaction play a role in diabetic
vascular complications. Inhibition of dipeptidyl peptidase-4 (DPP-4) is a potential therapeutic target for type
2 diabetes. However, the role of DPP-4 in AGE-induced endothelial cell (EC) damage remains unclear.
Methods: In this study, we investigated the effects of DPP-4 on reactive oxygen species (ROS) generation and
RAGE gene expression in ECs. We further examined whether an inhibitor of DPP-4, linagliptin inhibited AGE-induced
soluble DPP-4 production, ROS generation, RAGE, intercellular adhesion molecule-1 (ICAM-1) and plasminogen
activator inhibitor-1 (PAI-1) gene expression in ECs.
Results: DPP-4 dose-dependently increased ROS generation and RAGE gene expression in ECs, which were
prevented by linagliptin. Mannose 6-phosphate (M6P) and antibodies (Ab) raised against M6P/insulin-like growth
factor II receptor (M6P/IGF-IIR) completely blocked the ROS generation in DPP-4-exposed ECs, whereas surface
plasmon resonance revealed that DPP-4 bound to M6P/IGF-IIR at the dissociation constant of 3.59 x 10-5 M. AGEs or
hydrogen peroxide increased soluble DPP-4 production by ECs, which was prevented by N-acetylcysteine, RAGE-Ab
or linagliptin. Linagliptin significantly inhibited the AGE-induced ROS generation, RAGE, ICAM-1 and PAI-1 gene
expression in ECs.
Conclusions: The present study suggests that AGE-RAGE-induced ROS generation stimulates the release of DPP-4
from ECs, which could in turn act on ECs directly via the interaction with M6P/IGF-IIR, further potentiating the
deleterious effects of AGEs. The blockade by linagliptin of positive feedback loop between AGE-RAGE axis and
DPP-4 might be a novel therapeutic target for vascular injury in diabetes.
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The pathological role of the non-enzymatic modification
of amino groups of proteins, nucleic acids and lipids by
reducing sugars such as glucose, a process that is also
known as “Maillard reaction”, has become increasingly
evident in various types of diseases [1-3]. It is now well
established that early glycation products undergo further
progressive modification over time in vivo to the forma-
tion of irreversibly cross-linked senescent macroprotein
derivatives termed “advanced glycation end products
(AGEs)” [1-3]. The formation and accumulation of AGEs
in various tissues have been known to progress at a
physiological aging and at an accelerated rate under
hyperglycemic conditions [1-3]. There is accumulating
evidence that AGEs elicit oxidative stress generation and
subsequently evoke inflammatory and thrombogenic re-
actions in a variety of cells through the interaction with
the receptor for AGEs (RAGE), thereby being involved
in vascular complications in diabetes [4-9].
Dipeptidyl peptidase-4 (DPP-4), also known as CD26, is
a type II transmembrane glycoprotein expressed on vari-
ous cell types with multifunctional properties [10,11].
DPP-4 not only plays a role in T cell activation and prolif-
eration, but also modulates the physiological activity
of many regulatory peptides, because it is involved in
the cleavage of N-terminal amino acids from several
chemokines and neuropeptides [10,11]. Incretins such as
glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptides (GIP) are gut hormones se-
creted from L and K cells in the intestine in response to
food intake, respectively [12,13], both of which are target
proteins of DPP-4 and rapidly degraded and inactivated by
this proteolytic enzyme [10,11]. Since GLP-1 and GIP aug-
ment glucose-induced insulin release from pancreatic
b-cells, suppresses glucagon secretion, and slows gastric
emptying [12,13], inhibition of DPP-4 has been proposed
as a potential therapeutic target for the treatment of type
2 diabetes. However, it remains unclear DPP-4 inhibition
could have beneficial effects on AGE-exposed endothelial
cells (ECs). In other words, whether DPP-4 itself is in-
volved in vascular injury in diabetes remains unknown.
DPP-4 and D-Mannose-6-phosphate/insulin-like growth
factor II receptor (M6P/IGF-IIR) interaction contributes
to T cell activation [14]. Therefore, in this study, we first
investigated whether DPP-4 could directly act on human
umbilical vein ECs (HUVECs) to stimulate reactive oxygen
species (ROS) generation and RAGE gene induction via
the interaction with M6P/IGF-IIR. We next examined the
effects of AGEs on soluble DPP-4 production released
from HUVECs. We further studied whether an inhibitor
of DPP-4, linagliptin inhibited the AGE-induced soluble
DPP-4 production, ROS generation, RAGE, intercellular
adhesion molecule-1 (ICAM-1) and plasminogen activator
inhibitor-1 (PAI-1) gene expression in HUVECs.Methods
Materials
An inhibitor of DPP-4, linagliptin was generously gifted
from Boehringer Ingelheim (Ingelheim, Germany). Bovine
serum albumin (BSA) (essentially fatty acid free and
essentially globulin free, lyophilized powder), D-Mannose-
6-phosphate (M6P) and N-acetylcysteine (NAC) were pur-
chased from Sigma (St. Louis, MO, USA). D-glyceraldehyde
from Nakalai Tesque (Kyoto, Japan). Recombinant human
DPP-4 from R&D systems (Minneapolis, MN, USA).
Hydrogen peroxide (H2O2) from Wako Pure Chemical In-
dustries Ltd. (Osaka, Japan). Antibody (Ab) directed against
human M6P/insulin-like growth factor II receptor (IGF-
IIR) (M6P/IGF-IIR-Ab) and DPP-4 from Santa Cruz Bio-
technology Inc. (Delaware, CA, USA).
Cells
HUVECs were cultured in endothelial basal medium
supplemented with 2% fetal bovine serum, 0.4% bovine
brain extracts, 10 ng/ml human epidermal growth factor
and 1 μg/ml hydrocortisone according to the supplier’s
instructions (Clonetics Corp., San Diego, CA). DPP-4 or
AGE treatment was carried out in a medium lacking epi-
dermal growth factor and hydrocortisone.
Dihydroethidium (DHE) staining
HUVEC were treated with or without the indicated con-
centrations of DPP-4, 100 μg/ml AGE-BSA or 100 μg/ml
non-glycated BSA in the presence or absence of 50 μM
M6P, 5 μg/ml M6P/IGF-IIR-Ab, 10 nM or 0.5 μM
linagliptin for 4 hr, and then the cells were incubated
with phenol red free Dulbecco's Modified Eagle Medium
containing 3 μM DHE (Molecular Probes Inc., Eugene,
OR, USA). After 15 minutes, the cells were imaged
under a laser-scanning confocal microscope. Superoxide
generation was evaluated by intensity of DHE staining.
The intensity was analyzed by microcomputer-assisted
NIH image.
Surface plasmon resonance (SPR)
Recombinant human IGF-IIR (100 μg/ml, R&D system)
was immobilized via the amino groups to CM5 sensor
chip (GE Healthcare, Buckinghamshire, UK) with the aid
of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide and
N-hydroxysuccinimide. For affinity measurements, the
association and dissociation phases were monitored in a
BIAcore 1000 (GE Healthcare). Recombinant human
DPP-4 was injected into the flow cell at concentrations
of 0.1 and 0.3 μM at a flow rate of 10 μl/min at 25°C.
The sensor chip was regenerated with pulses of 20 mM
Tris–HCl buffer (pH 8.0) containing 6 M urea to the
baseline level, followed by an extensive washing with the
running buffer. Control experiments were performed
with IGF-IIR-free channel on the same sensor chip.
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flecting the bulk effect of buffer, were subtracted using
BIA-evaluation 4.1 software (GE Healthcare). Equilib-
rium dissociation constant (KD) was determined using
the equation for 1:1 Langmuir binding.
Real-time reverse transcription-polymerase chain
reactions (RT-PCR)
HUVEC were treated with or without the indicated con-
centrations of DPP-4, 100 μg/ml AGE-BSA or 100 μg/ml
non-glycated BSA in the presence or absence of 10 nM
or 0.5 μM linagliptin for 4 hr. Then total RNA was
extracted with RNAqueous-4PCR kit (Ambion Inc.,
Austin, TX, USA) according to the manufacturer’s instruc-
tions. Quantitative real-time RT-PCR was performed using
Assay-on-Demand and TaqMan 5 fluorogenic nuclease
chemistry (Applied Biosystems, Foster city, CA, USA)
according to the supplier’s recommendation. IDs of primers
for human RAGE, ICAM-1, PAI-1, β-actin and 18S gene
were Hs00153957_m1, Hs00164932_m1, Hs01126606_m1,
Hs99999903_m1, and Hs99999901_s1, respectively.
Preparation of AGE-BSA
AGE-BSA was prepared as described previously [15]. In
brief, BSA (25 mg/ml) was incubated under sterile condi-
tions with 0.1 M glyceraldehyde in 0.2 M NaPO4 buffer
(pH 7.4) for 7 days. Then unincorporated sugars were re-
moved by PD-10 column chromatography and dialysis
against phosphate-buffered saline. Control non-glycated
BSA was incubated in the same conditions except for the
absence of reducing sugars. Preparations were tested for
endotoxin using Endospecy ES-20S system (Seikagaku
Co., Tokyo, Japan); no endotoxin was detectable.
Preparation of Ab raised against RAGE (RAGE-Ab)
Ab directed against human RAGE was prepared as de-
scribed previously [16].
Soluble DPP-4 production
HUVECs were treated with or without 100 μg/ml AGE-
BSA, 100 μg/ml non-glycated BSA or the indicated con-
centrations of H2O2 in the presence or absence of 1 mM
NAC, 5 μg/ml RAGE-Ab or 10 nM linagliptin for 24 hr.
Conditioned medium were collected and concentrated
20-fold using an Amicon ultrafiltration system (5000-
kDa cutoff, Merck Millipore, Darmstadt, Germany)
according to the method described previously [16]. Then
20 μg proteins were separated by SDS-PAGE and trans-
ferred to polyvinylidene difluoride membranes as de-
scribed previously [17]. Membranes were probed with
Ab directed against human DPP-4, and then immune
complexes were visualized with an enhanced chemilu-
minescence detection system (Amersham Bioscience,
Buckinghamshire, United Kingdom).Statistical analysis
Unless otherwise indicated, all values were presented as
means ± SE from at least 3 independent experiments.
Statistical analyses were performed by one-way ANOVA
followed by the Scheffe F test for multiple comparisons,
and p < 0.05 was considered statistically significant. All
statistical analyses were performed with the use of the
PASW Statistics system (version 18.0; IBM Corporation,
New York, NY, USA).
Results
We first examined the effects of DPP-4 on ROS gener-
ation in HUVECs. As shown in Figure 1A and 1B, DPP-
4 dose-dependently increased superoxide generation in
HUVECs; 500 ng/ml DPP-4-induced increase in ROS
generation was completely blocked by the treatment
with 10 nM linagliptin, 50 μM M6P or 5 μg/ml M6P/
IGF-IIR-Ab. M6P or M6P/IGF-IIR alone did not affect
superoxide generation in HUVECs. Figure 1C shows the
representative binding sensorgram of 0.1 and 0.3 μM
DPP-4 to immobilized M6P/IGF-IIR. SPR analysis re-
vealed that DPP-4 bound to M6P/IGF-IIR; KD value was
3.59 × 10-5 ± 1.35 × 10-5 M. Furthermore, DPP-4 dose-
dependently RAGE gene expression in HUVECs, which
was also blocked by linagliptin (Figure 1D).
We next examined whether AGEs could stimulate
soluble DPP-4 generation by HUVECs. As shown in
Figure 2A, AGEs increased DPP-4 production released
from HUVECs, which was significantly prevented by the
treatment with an anti-oxidant, NAC, RAGE-Ab or
linagliptin. Moreover, H2O2 dose-dependently stimulated
the release of DPP-4 from HUVECs (Figure 2B).
We further investigated the effects of linagliptin on
AGE-exposed HUVEC. As shown in Figure 3, AGEs
stimulated superoxide generation and up-regulated m
RNA levels of RAGE, ICAM-1 and PAI-1 in HUVECs,
all of which were significantly blocked by linagliptin.
Discussion
Role of DPP-4 in vascular injury
M6P/IGF-IIR has been shown to work as a receptor for
DPP-4 in HUVECs and mediates its biological action, re-
sultantly promoting transendothelial T cell migration,
and an effect requires the enzymatic activity of DPP-4
[18]. In this study, we found for the first time that
blocking the interaction of DPP-4 with M6P/IGF-IIR by
the addition of excess amount of free M6P or M6P/IGF-
IIR-Ab completely inhibited the DPP-4-induced increase
in superoxide generation in HUVECs. Further, SPR ana-
lysis revealed that DPP-4 actually bound to M6P/IGF-
IIR, and an inhibitor of DPP-4, linagliptin completely
prevented the ROS generation and up-regulation of
RAGE mRNA levels in DPP-4-exposed HUVECs. Since
we have previously shown that AGEs stimulate RAGE
Figure 1 Effects of DPP-4 on ROS generation (A and B) and RAGE gene expression (D) in HUVECs and (C) representative binding
sensorgram of DPP-4 to immobilized M6P/IGF-IIR. HUVEC were treated with or without the indicated concentrations of DPP-4 in the
presence or absence of 50 μM M6P, 5 μg/ml M6P/IGF-IIR-Ab, or 10 nM linagliptin for 4 hr. (A and B) Then the cells were incubated with DHE.
Upper panel shows typical microphotographs of the cells. Lower panel shows quantitative data of ROS generation evaluated by fluorescent
intensity. (A) N = 12 per group. (B) N = 27 per group. (D) Total RNAs were transcribed and amplified by real-time PCR. Data were normalized by
the intensity of β-actin mRNA-derived signals and then related to the value obtained with control. N = 3 per group. (C) DPP-4 at 0.1 and 0.3 μM
was injected on the sensor chip immobilized M6P/IGF-IIR. N = 3 per group. * and **, p < 0.05 and p < 0.01 compared to the value with
control, respectively.
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present observations suggest that DPP-4 could increase
ROS generation and subsequently RAGE gene over-
expression in HUVECs through the interaction with
M6P/IGF-IIR, whose ability is totally dependent on
its intrinsic DPP-4 enzymatic activity. AGEs have been
shown to impair the migration, adhesion and secretion
potentials of late endothelial progenitor cells [19,20].
Further, AGE-RAGE interaction causes inflammation
and thrombogenesis in diabetic vessels [21,22]. There-
fore, given the atherosclerosis-promoting properties of
AGE-RAGE axis, although the reason why DPP-4 caused
vascular damage in diabetes remains unclear, DPP-4itself might be involved in diabetic vascular injury. DPP-
4 has been reported to not only stimulate proliferation
of human coronary artery smooth muscle cells [23], but
also contribute to monocyte migration, macrophage-
mediated inflammatory reactions and tissue remodeling
[24,25], thus supporting the speculation that DPP-4 itself
might work as a risk factor for atherosclerosis.
Crosstalk between AGE-RAGE axis and DPP-4
In this study, AGEs stimulated the release of DPP-4
from HUVECs, which was significantly inhibited by the
treatment with an anti-oxidant, NAC, RAGE-Ab, or
linagliptin. Moreover, H2O2 dose-dependently increased
Figure 2 Effects of AGEs on DPP-4 production released from HUVECs. HUVECs were treated with or without 100 μg/ml AGE-BSA, 100 μg/ml
non-glycated BSA or the indicated concentrations of H2O2 in the presence or absence of 1 mM NAC, 5 μg/ml RAGE-Ab or 10 nM linagliptin for
24 hr. Conditioned medium were collected and concentrated 20-fold using an Amicon ultrafiltration system. Then 20 μg proteins were separated
by SDS-PAGE and transferred to polyvinylidene difluoride membranes. Soluble DPP-4 expression released from the cells was measured. Each
upper panel shows the representative bands. Lower panel shows the quantitative data. (A) N = 3 per group. (B) N = 9 per group.
Ishibashi et al. Cardiovascular Diabetology 2013, 12:125 Page 5 of 9
http://www.cardiab.com/content/12/1/125the production of soluble DPP-4 by HUVECs. So, the
AGE-RAGE-induced ROS generation could be involved
in soluble DPP-4 generation by HUVECs. The present
findings have extended our previous observations [17]
showing that serum levels of AGEs were independently
correlated with circulating DPP-4 values in 432 consecu-
tive outpatients and that AGEs significantly increase sol-
uble DPP-4 release from cultured proximal tubular cells,
one of the major cell types that expressed DPP-4 in
humans [26]. Since we previously reported that AGEs at
100 μg/ml for 4 hr did not affect DPP-4 mRNA levels in
HUVECs [27], the AGE-RAGE interaction might pro-
mote the proteolytic cleavage of membrane-bound DPP-
4 from HUVECs via superoxide generation. Serum levels
of AGEs are positively rather than inversely associated
with soluble form of RAGE (sRAGE) (endogenous
secretory RAGE plus cleaved RAGE) in both diabetic
and non-diabetic subjects [28,29]. Therefore, although
exogenously administered sRAGE was shown to block
the harmful effects of AGEs in animals by acting as a
decoy receptor, it is questionable that sRAGE in humans
could also exert the same biological effect, because its
serum concentration is 1000 times lower than neededfor efficiently capturing and eliminating the circulating
AGEs [30]. Moreover, engagement of RAGE with its lig-
and has been shown to promote the RAGE shedding
[30,31]. These findings suggest that sRAGE level could
reflect tissue RAGE expression and that AGEs might en-
hance the cleavage of DPP-4 from the cell membrane.
Given the facts that serum DPP-4 activity is largely asso-
ciated with circulating DPP-4 levels [10,32] and that 20%
of incretins derived from gastrointestinal tract are still
alive in the blood pool [33,34], cumulative hypergly-
cemia and resultant AGE accumulation might impair
the incretins’ effects via elevation of circulating DPP-4
levels, further deteriorating glycemic control and thereby
forming a vicious cycle in diabetic subjects. This sce-
nario could support the clinical relevance of blockade of
the pathological crosstalk between AGE-RAGE axis and
DPP-4 by linagliptin in the treatment with type 2 diabetes.
Protective role of linagliptin against AGE-RAGE-induced
vascular damage in diabetes
In the present study, we found that linagliptin signifi-
cantly inhibited the AGE-induced ROS generation,
RAGE, ICAM-1 and PAI-1 gene expression in HUVECs.
Figure 3 Effects of linagliptin on AGE-exposed HUVECs. HUVECs were treated with 100 μg/ml AGE-BSA or non-glycated BSA in the presence
or absence of 10 nM or 0.5 μM linagliptin for 4 hr. (A) Cells were incubated with DHE. Upper panel shows typical microphotographs of the cells.
Lower panel shows quantitative data of ROS generation evaluated by fluorescent intensity. N = 50 per group. (B-D) Total RNAs were transcribed
and amplified by real-time PCR. Data were normalized by the intensity of β-actin (B) or 18S mRNA-derived signals (C and D) and then related to
the value obtained with non-glycated BSA. (B) N = 15 per group. (B) N = 15 per group. (C and D) N = 9 per group. * and **, p < 0.05 and p < 0.01
compared to the value with AGEs alone, respectively.
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sion in a variety of cells via ROS generation and induce
activation of redox-sensitive transcriptional factor, NF-
kB and subsequent ICAM-1 and PAI-1 gene induction
[7,15,31,35-37]. Therefore, the AGE-RAGE-induced oxi-
dative stress generation could further potentiate the
harmful effects of AGEs via RAGE overexpression. So,
linagliptin might inhibit the AGE-evoked inflammatory
and thrombogenic responses in HUVECs by blockingthe positive feedback loops between ROS generation and
RAGE gene up-regulation. In this study, we could not
clarify the mechanism by which linagliptin inhibited the
AGE-induced ROS generation in HUVECs. However, we
have previously shown that GLP-1 and GIP protect
against AGE-induced HUVEC damage via anti-oxidative
properties through the elevation of cyclic AMP, whose
effect is augmented by the addition of DPP-4 inhibitor
[27,38,39]. Since AGE-RAGE axis evokes ROS generation
Figure 4 Possible crosstalk between AGE-RAGE axis and soluble DPP-4.
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cAMP-elevating agents [6,7,15,40], linagliptin could en-
hance the beneficial effects of incretins on AGE-exposed
HUVECs by inhibiting NADPH oxidase activity. Further-
more, we have recently found that linagliptin contains
xanthine scaffold structure, which could inhibit xanthine
oxidase activity in vitro [41]. The anti-oxidative unique
properties of this drug might also be involved in the block-
ade of vicious cycle between ROS generation and RAGE
gene induction. It is unlikely that linagliptin directly
inhibited the AGE-RAGE interaction because highly sensi-
tive 27-MHz quartz crystal microbalance analysis (Affinix
Q; Initium, Tokyo, Japan) revealed that linagliptin can not
bind to AGEs in vitro (data not shown).
One early phase of atherosclerosis involves the recruit-
ment and firm adhesion of inflammatory cells to ECs,
whose process is mediated by adhesion molecules such as
ICAM-1 [42,43]. Further, attenuated fibrinolytic activity due
to increased PAI-1 levels is prevalent in diabetic patients,
thus contributing to the increased risk of atherothrombosis
in these subjects [37,44,45]. Linagliptin may be a promising
strategy for not only ameliorating hyperglycemia in type 2
diabetic patients, but also protecting against vascular injury
by suppressing ICAM-1 and PAI-1 expression through
blockade of the deleterious effects of AGE-RAGE axis
partly via inhibition of DPP-4 and M6P/IGF-IIR interaction.
In pre-specified meta-analysis of cardiovascular events in
linagliptin or comparator-treated patients with type 2
diabetes mellitus, the hazard ratio for a composite of
cardiovascular death, stroke, myocardial infarction, and
hospitalization for unstable angina showed significantly
lower risk with linagliptin than comparator [46]. Moreover,
we have very recently found that DPP-4 inhibitor alogliptintreatment blocks the AGE-RAGE axis and resultantly
reduces albuminuria in type 2 diabetes patients [47]. Fluor-
escent AGE levels have also been shown to be an independ-
ent marker of post-infarction heart failure development risk
[48]. These data reinforce the important clinical implica-
tions of the present findings of linagliptin.
The peak plasma concentration of linagliptin after ad-
ministration of single oral dose of 5 mg is reported to be
about 10 nM [49]. So, the concentration of linagliptin
having beneficial effects on HUVECs used in the present
experiments (10 nM) may also be comparable to the
therapeutic level which is achieved in the treatment for
patients with type 2 diabetes.Limitations
Our study has several limitations that should be noted.
First, we did not examine here the effect of M6P/IGF-
IIR-Ab on the increase in ROS generation induced by
AGEs or the increase in RAGE gene expression induced
by DPP-4 and AGEs. Second, although mRNA levels of
DPP-4 were not changed by the treatment with AGEs,
the effect of linagliptin on membrane DPP-4 expression
in AGE-exposed HUVECs remains unknown. Additional
experiments would strengthen the present findings.Conclusions
Our present observations suggest AGEs could stimulate
the release of DPP-4 from HUVECs via RAGE-mediated
ROS generation, which may further augment the AGE-
RAGE signaling to EC damage through the interaction
with M6P/IGF-IIR (Figure 4).
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